|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,413,000 |
Market
Cap: |
9.73(B) |
Last
Volume: |
909,295 |
Avg
Vol: |
504,661 |
52
Week Range: |
$114.17 - $208.42 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,500 |
1,500 |
Total Buy Value |
$0 |
$0 |
$238,260 |
$238,260 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
25,597 |
29,385 |
30,235 |
146,471 |
Total Sell Value |
$5,039,534 |
$5,596,862 |
$5,742,535 |
$29,817,809 |
Total People Sold |
4 |
5 |
5 |
6 |
Total Sell Transactions |
4 |
5 |
6 |
17 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hunt Anthony |
Chief Executive Officer |
|
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,437 |
243,764 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,686 |
27,340 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,410 |
35,908 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2021-01-25 |
4 |
OE |
$33.87 |
$135,480 |
D/D |
4,000 |
33,498 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2021-01-04 |
4 |
AS |
$188.69 |
$757,840 |
D/D |
(3,957) |
29,498 |
|
-11% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-12-16 |
4 |
S |
$186.18 |
$80,988 |
D/D |
(435) |
25,654 |
|
-20% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-11-19 |
4 |
AS |
$184.69 |
$3,716,051 |
D/D |
(20,000) |
233,327 |
|
4% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-11-19 |
4 |
OE |
$26.05 |
$521,000 |
D/D |
20,000 |
253,327 |
|
- |
|
Ryan Thomas F Jr |
Director |
|
2020-11-11 |
4 |
S |
$187.73 |
$175,340 |
D/D |
(934) |
1,464 |
|
3% |
|
Ryan Thomas F Jr |
Director |
|
2020-11-11 |
4 |
OE |
$38.76 |
$36,202 |
D/D |
934 |
2,398 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-11-10 |
4 |
S |
$193.00 |
$595,598 |
D/D |
(3,086) |
33,455 |
|
-11% |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-11-10 |
4 |
OE |
$32.40 |
$99,986 |
D/D |
3,086 |
36,541 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-11-09 |
4 |
OE |
$59.52 |
$112,671 |
D/D |
1,893 |
33,455 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-11-09 |
4 |
S |
$194.69 |
$137,256 |
D/D |
(705) |
31,562 |
|
-8% |
|
Barthelemy Nicholas |
Director |
|
2020-11-09 |
4 |
S |
$195.51 |
$237,349 |
D/D |
(1,214) |
1,450 |
|
-8% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-09-10 |
4 |
AS |
$146.85 |
$6,721,018 |
D/D |
(45,351) |
233,327 |
|
50% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-09-10 |
4 |
OE |
$26.05 |
$1,181,394 |
D/D |
45,351 |
278,678 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-08-06 |
4 |
S |
$153.79 |
$768,950 |
D/D |
(5,000) |
26,089 |
|
-23% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-08-06 |
4 |
OE |
$33.87 |
$169,350 |
D/D |
5,000 |
31,089 |
|
- |
|
Ryan Thomas F Jr |
Director |
|
2020-07-31 |
4 |
S |
$151.77 |
$470,129 |
D/D |
(3,095) |
1,464 |
|
-20% |
|
Ryan Thomas F Jr |
Director |
|
2020-07-31 |
4 |
OE |
$67.71 |
$142,800 |
D/D |
2,109 |
4,559 |
|
- |
|
Dawes Karen A |
Director |
|
2020-06-18 |
4 |
AS |
$113.58 |
$2,154,851 |
D/D |
(18,705) |
100,734 |
|
51% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-05-21 |
4 |
OE |
$16.55 |
$1,206,140 |
D/D |
50,039 |
233,327 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-05-21 |
4 |
AS |
$139.17 |
$6,562,409 |
D/D |
(46,953) |
230,241 |
|
6% |
|
Dawes Karen A |
Director |
|
2020-05-20 |
4 |
AS |
$135.91 |
$72,093 |
D/D |
(517) |
119,439 |
|
8% |
|
636 Records found
|
|
Page 9 of 26 |
|
|